Why does reimbursement of orphan drugs require a specific approach?
Journal Title: OncoReview - Year 2011, Vol 1, Issue 1
Abstract
The greatest problem concerning the reimbursement of orphan products is their high price. In the case of orphan drugs, reimbursement and pricing decisions are highly interrelated. In decisions concerning reimbursement of newly marketed health technologies, their cost-effectiveness or cost-utility should be taken into account. Rigorousness and thoroughness of evaluating an orphan drug prior to a reimbursement or pricing decision should depend on the cost of treatment and it should be stressed that for most orphan interventions costs of treatment depends mainly on the price of the orphan product. Low cost orphan drugs should be managed as all other drugs which do not generate high treatment costs. In the case of high and very high cost orphan drugs much more restrictive procedures should be applied in its assessment. Apparently, assessment of a very high cost orphan drug should be performed and appropriate analyses should be prepared by the applicant. Alternatively, the technology may be assessed by the HTA Agency itself. Appraisal should be performed by a separate advisory body, e.g. The Rare Diseases Team to the Minister of Health. The final decision should be made by the Minister of Health, who will bear political responsibility. In Poland appropriate state authorities have to undertake specific professional pricing activities with respect to orphan products in egalitarian approach and introduce risk sharing agreements by Law.
Authors and Affiliations
Krzysztof Łanda, Jakub Adamski
Keywords
Related Articles
- EP ID EP53087
- DOI -
- Views 291
- Downloads 0
Invasive fungal infection in a child with Ewing’s sarcoma
Invasive fungal infection (IFI) in patients with malignant solid tumours is rare, but it highly increases the risk of cancer recurrence because of prolonged discontinuation of cancer treatment. This paper presents a case...
Pericardiocentesis and pericardial therapy aspects in cancer patients - a case report
The malignancy related pericardial effusion has variable dynamics, and the clinical presentation and severity of symptoms are directly related to the degree of hemodynamic conditions and the rate of fluid accumulation in...
Off-label drug use in breast cancer therapy
Breast cancer is one of the most common malignancies across the world, including Poland. Chemotherapy plays an important part in the treatment of the disease. Most of the available chemotherapy drugs and regimens have un...
Tumor lysis syndrome
Tumor lysis syndrome is a life-threatening oncological emergency occurring in response to chemotherapy or spontaneously as a result of massive and rapid breakdown of malignant cells. The release of their contents into ci...
Arterial hypertension related to sunitinib
Hypertension is a common concomitant disease in patients with renal carcinoma and a frequent complication of sunitinib therapy. Blocking of VEGF-dependent pathway leads to endothelial dysfunction, reduced nitric oxide pr...